Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

Next Previous
Trial Profile

Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ELOQUENT-2
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 17 Jun 2022 Extended 3 year follow-up results assessing efficacy and safety of elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma, presented at the 27th Congress of the European Haematology Association.
  • 07 Jun 2022 Results of an analysis the synthetic control arm potential of derived from EHR to provide additional support for trials investigating treatment efficacy in multiple myeloma presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top